Kornimate/medical-research-clean huggingface dataset:
continuous glucose monitoring in type 2 diabetes mellitus

Conditions: Diabetic Vascular Complications

Summary: it is well known that lowering average blood glucose decreases the risk of diabetic complications involving the small vessels, such as those found in the eyes, nerves and kidney. it is less clear however, if controlling fluctuations in blood glucose will further help to prevent such complications. the purpose of this study is to examine the relationship between extreme fluctuations in glucose and damage to the blood vessel lining.

studies have shown that glycemic variability is associated with oxidative stress which in turn has been correlated with endothelial damage. further, endothelial damage has been identified as a critical event lending way to the vascular complications seen in many disease states. the specific aim of this study is to investigate the relationship between short-term glycemic variability and biomarkers of endothelial dysfunction while analyzing the influence of different variables and adjusting for covariates. data obtained from a continuous glucose monitoring system(cgms), a device that continuously records interstitial glucose for a 72 hour period, is used to calculate glycemic variability. serology for the determination of endothelial dysfunction biomarkers is obtained on day three. pearson and spearman rank order correlations are utilized to determine whether there are any significant correlations between measures of glycemic variability and biomarker levels of endothelial dysfunction. multiple regression analysis would also determine if glycemic variability predicts elevated biomarker levels even after controlling for other variables. provided the high prevalence of diabetic complications and their staggering socioeconomic costs, it is important to elucidate the relationship between glycemic variability and endothelial dysfunction.

Eligibility criteria:
inclusion criteria: * adult subjects with type 2 diabetes mellitus and glycosylated hemoglobin \<8.0% exclusion criteria: * age \ 65 * bmi \>35 * pregnant * baseline glycosylated hemoglobin \ 8.0% * winthrop university hospital employee or staff member * vulnerable subject * uncontrolled hypertension(defined as systolic blood pressure \>130 or diastolic blood pressure \>80mmhg) * uncontrolled dyslipidemia (defined as ldl \>130mg/dl; hdl \ 199mg/dl) * current smoker or significant smoke exposure(defined as greater than 2 hours of exposure to second-hand smoke within the preceding 48hrs) * sympathomimetic use within the past week * history of cardiovascular disease * history of paroxysmal nocturnal hemoglobinuria * history of thrombotic thrombocytopenic purpura * history of stage ii-v chronic kidney disease

Keywords: glycemic variability endothelial dysfunction
carelizumab combined with regorafenib in the treatment of hcc（care-2020）

Conditions: Hepatocellular Carcinoma

Summary: to investigate the efficacy and safety of carelizumab combined with regorafenib in second-line treatment for patients with primary hepatocellular carcinoma.

currently, there is little experience in the application of targeted drugs combined with immunotherapy. through this study, we hope to explore the optimal population for the use of carelizumab combined with regorafenib in the second-line treatment of hepatocellular carcinoma (hcc), as well as the efficacy and safety. this research is a single-center trials phase ii second-line, single arm, explore the clinical outcome of treatment.

Eligibility criteria:
inclusion criteria: * not convenient to disclose exclusion criteria: * not convenient to disclose
a long-term study of healthy adults vaccinated with one dose of smallpox vaccine (lister strain)

Conditions: Smallpox

Summary: the purpose of this study is to provide long-term follow-up immunogenicity and safety data on participants who were vaccinated with the second-generation smallpox vaccine in study vvl04 (nct 00258947). primary objectives: immunogenicity: to yearly describe the vaccinia antibody persistence up to 5 years post-vaccination. safety: to follow-up the long-term safety up to 5 years post-vaccination.

none of the participants in this study will receive any vaccination as part of the study. all participants will provide blood samples for immunogenicity testing at the 1, 2, 3, 4, and 5 year anniversaries of vaccination. safety will be assessed for up to 5 years after vaccination, including follow-up of reactions that occurred during study vvl04 (nct 00258947).

Eligibility criteria:
inclusion criteria : * subject vaccinated and who completed the phase ii vvl04 trial. * informed consent form signed. * subject able to comply with all trial procedures. * subject entitled to national social security. exclusion criteria : * subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.

Keywords: smallpox vaccinia virus smallpox vaccine variola virus
creation of the biobank related to eye disease

Conditions: Eye Diseases

Summary: the purpose of this study is to develop a biobank (a specialized lab) and collect blood, fluids and/or other tissue samples to study eye diseases.

the purpose of the biobank related to eye disease at beaumont hospital is to help connect specialties and specialists with each other, outside traditional limits of hospital or laboratory departments. the specimens (blood, fluids, and/or tissue samples) that will be collected from men, women and children will assist the researchers in a variety of studies on human eye diseases. research utilizing these specimens will allow for an increased understanding of the etiology, disease process, and response to treatments for various eye diseases, and will provide opportunities to subsequently improve our management decisions. furthermore, projects that cross over between subspecialties are sparse and that is a limiting factor for the development of research that takes a more comprehensive approach.

Eligibility criteria:
inclusion criteria: all pediatric and adult patients age 0-99 years - exclusion criteria: all patients who do not agree to consent for collection of blood, fluids, tissue. patients who are cognitively impaired and are not able to verbalize understanding of the risks/benefits. -

Keywords: biobank genetics
cranio- cervical flexion training with and without pressure biofeedback in mechanical neck pain

Conditions: Mechanical Neck Pain

Summary: the superficial neck flexor musculature has been given considerate amount of attention to explore its effects on the cervical pain in several researches.. this study intends to put through the benefits of deep cervical flexor training for treatment of cervical neck pain patients.this study will also compare the effects of cranio cervical flexion training with and without pressure biofeedback on neck pain, muscular endurance,forward head posture and cervical mobility in mechanical neck pain.

the study is randomized control trail, which is being conducted in physical therapy outpatient department of pakistan railway hospital. sample size of 24 individual was calculated using epitool with 95% confidence interval (ci) and power 80%. individual will be screened out according to inclusion criteria. individuals will be allocated randomly into two groups, 12 in craniocervical flexion training with pressure biofeedbackgroup and 12 in craniocervical flexion training without pressure biofeedbackgroup by sealed envelope method. deep neck flexor endurance techniquewas used totrain thecraniocervical flexor muscles in control group.craniocervical flexion technique with pressure biofeedback unit's was positioned behind the neck just below the occiput was used to train the endurance of the craniocervical flexor muscle in experimental group. assessment will be done on baseline and 4th week. data will be analyzed on spss version 21.

Eligibility criteria:
inclusion criteria: * • patients with chronic mechanical neck pain for more than 3 months duration * subjects with aged 25-40 years * numeric pain rating scale (nrps) greater than 3. * patients with forward neck posture and a craniovertebral angle less than 48° exclusion criteria: * • history of neck surgery, cervical trauma spinal cord compression, spinal tumor, spinal instability * history of spinal fracture, inflammatory disease of spine, spinal infections, significant neurological deficit, congenital or acquired postural deformity, doing prescribed exercise for cervical spine. * neck or shoulder pain from non-musculoskeletal causes, demonstrated neurological signs, or had a history of malignancy, current pregnancy.

Keywords: endurance training,
impact of obicetrapib and obicetrapib plus repatha on lp(a) levels

Conditions: Dyslipidemias

Summary: the goal of this open label 16 week trial is to evaluate lp(a) levels for patients with elevated lp(a) being treated with obicetrapib and obiceptrapib/evolocumab patients will: have baseline lp(a) tested at randomization take 10mg/dl obiceptrapib daily for 8 weeks and have lp(a) tested at week 8 take 10 mg/dl obicetrapib daily/evolocumab 140 every other week for 8 weeks and have lp(a) retested at week 16


Eligibility criteria:
inclusion criteria: * lp(a) \>50 mg/dl * ldl-c \>70 mg/dl * tg \< 400mg/dl exclusion criteria: * hba1c\>=10 or fpg \>=270 mg/dl * cv events within 3 months of screen
website for adolescents about pediatric clinical trials

Conditions: Healthy; Chronic Illnesses, Multiple

Summary: the goal of this study is to evaluate the effectiveness of digiknowit news: teen with parent-adolescent pairs.

parent-adolescent pairs (n=180) will be recruited to participate in a randomized controlled trial. parent consent and parent permission and youth assent will be sought. participant pairs will be randomized into one of two study arms: intervention and wait-list control. all participants will complete a web-based pre-test questionnaire. youth and parents in the intervention group will then receive access to digiknowit news: teen for one week. approximately one week after completing the pre-test questionnaire, all participants will complete a web-based post-test questionnaire (the post-test for the intervention group will include consumer satisfaction questions). youth and parents in the wait-list control group will then receive access to digiknowit news: teen for one week. after one week, they will be asked to complete a consumer satisfaction questionnaire.

Eligibility criteria:
inclusion criteria: * adult participant is a parent or legal guardian of adolescent participant; * adolescent participant is within the ages of 12-17 years; * parent-adolescent pair has access to a computer or tablet with internet connection * parent-adolescent pair is fluent in english exclusion criteria: * adolescent participant has previously participated in a clinical trial after kindergarten.
a study evaluating maintenance therapy after first line chemotherapy in metastatic cancer pancreas

Conditions: Cancer of Pancreas

Summary: a randomized phase ii study evaluating maintenance therapy after first line induction chemotherapy in metastatic cancer pancreas.

in this study, we aim to evaluate the role of maintenance capecitabine by comparing 2 arms of metastatic cancer pancreas patients in the first line , the first arm will receive 4 months of induction folfrinox the maintenance capecitabine and the second arm will receive 4 months of folfrinox then kept under follow-up: •primary end point: pfs. •secondary end points: os, qol and toxicity.

Eligibility criteria:
inclusion criteria: * histologically confirmed invasive adenocarcinoma of pancreas. * stage 4 disease according to the american joint committee on cancer (ajcc the 8th edition) 2017. * measurable metastases according to recist 1.1. * patients underwent surgical resection and postoperative evaluation revealed distant metastasis. * patients with age ranging from 18 to 69. * who performance status 0-1. * an adequate bone marrow reserve and adequate liver and renal function as follow: neutrophils ≥ 1500 cell/dl, platelets ≥ 100,000 cell/dl, hemoglobin ≥ 9.0 g/dl, total bilirubin \ 30 ml/min. * adjuvant and neoadjuvant chemotherapies will be permitted if administered more than 6 months before inclusion. * patients with biliary or gastroduodenal obstruction must have drainage or surgical bypass prior to starting chemotherapy. * all patients must have signed and dated informed consent form. exclusion criteria: * endocrine or acinar pancreatic carcinoma. * patients who progressed during folfrinox regimen. * pregnancy or breast feeding. * patients with complicated systemic diseases such as diabetes, htn or decompensated liver disease. * patients with any serious uncontrolled medical conditions that might compromise study participation: central nervous system disorders, gastrointestinal tract disorders that interfere with oral medication. * patients with history of previous other carcinoma except basal cell carcinoma of the skin, insitu cervical carcinoma or non-metastatic prostate cancer. * more than grade 1 peripheral neuropathy. * brain metastasis.
deep learning image reconstruction for abdominal ct of hepatocellular carcinoma compared with 3-tesla mri

Conditions: Hepatocellular Carcinoma

Summary: new algorithms for processing ct acquisitions, based on artificial intelligence, have been reported to improve acquisition quality. thats' why it's possible to imagine that new scan post-processing algorithms enable better detection and characterization of hepatocellular carcinoma lesions than with standard reconstructions. dlir reconstructions could even match with mri detection. the aim of the study is to compare the detection and characterization of hepatic lesions according to the li-rads classification in ct with dlir artificial intelligence reconstruction, compared with asir-v reconstruction and the gold standard of mri.


Eligibility criteria:
inclusion criteria: * undergoing ct and mri scans in the same week, with protocols dedicated to the detection of hcc lesions exclusion criteria: * imaging with radiological artefact

Keywords: hepatocellular carcinoma dlir ct asir reconstruction
goal: a research study looking at long term blood sugar control in people with type 2 diabetes treated with xultophy® in local clinical practice in japan.

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to collect information on how xultophy® works with other oral anti diabetic medication in patients with type 2 diabetes. participants will get xultophy® as prescribed by the study doctor. the study will last for about 26 weeks. participants will be asked questions about health and diabetes treatment and lab tests as part of normal doctor's appointment.


Eligibility criteria:
inclusion criteria: * signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * the decision to initiate treatment with commercially available xultophy® has been made by the patient/legally acceptable representative (lar) and the treating physician before and independently from the decision to include the patient in this study. * male or female, age above or equal to 20 years at the time of signing informed consent * diagnosed with t2dm (type 2 diabetes mellitus ) above or equal to 180 days prior to initiation of xultophy® treatment. * treated with any oral anti-hyperglycaemic medication(s), except for oral glp-1 ras, for at least 60 days prior to initiation of xultophy® treatment. * available and documented hba1c value less or equal to 12 weeks prior to initiation of xultophy® treatment. exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study. * participation in any clinical trial of an approved or non-approved investigational medicinal product within 30 days before prior to initiation of xultophy® (simultaneous participation in a trial with the primary objective of evaluating an approved or non-approved investigational medicinal product for prevention or treatment of covid-19 disease or postinfectious conditions is allowed if the last dose of the investigational medicinal product has been received more than 30 days before screening.). * treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 60 days prior to initiation of xultophy® treatment. however, short term insulin treatment for a maximum of 14 days prior to initiation of xultophy® treatment is allowed, as is prior insulin treatment for gestational diabetes. * previous treatment with xultophy®. * female who is known pregnant, breast-feeding or intends to become pregnant. * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. * known or suspected hypersensitivity to the active substance or to any of the excipients as specified in the approved xultophy® label in japan.
liver cirrhosis patients' digital health literacy and perspective on digital healthcare, a multicenter questionnaire study

Conditions: Liver Cirrhosis

Summary: the goal of this study is to investigate digital health literacy in liver cirrhosis patients. participants will fill in two questionnaires by email or mail.


Eligibility criteria:
inclusion criteria: * liver cirrhosis diagnosis, based on liver biopsy, fibroscan (elastography), radiographic imaging and/or clinical criteria according to applied guidelines at the time of inclusion * age 18 years or older * treated at gastroenterology department exclusion criteria: * objection to be approached for scientific studies requests, documented in electronic patient record

Keywords: health literacy
timing and dosage of acute intermittent hypoxia in persons with sci

Conditions: Spinal Cord Injuries

Summary: this study will utilize short duration and mild levels of reduced oxygen (hypoxia) to induce spinal plasticity while evaluating the appropriate timing schedule for this intervention, as well as, the effects of superimposing sessions of a therapy, in individuals with chronic incomplete sci. our aim is to establish the time-course of outcome improvement and decay following a single session or multiple sessions of aih therapy.


Eligibility criteria:
inclusion criteria: 1. spinal cord lesion at level of c3 to t1 2. individuals with a history of incomplete spinal cord injury, classified as asia c or d 3. individuals must be at least 6 months status post injury 4. individuals must be between the ages of 18-70 years inclusive, male or female 5. spinal cord injury must be secondary to a non-progressive etiology 6. individuals must be medically stable. 7. able to comply with protocol/study requirements 8. not currently (\>2 weeks) taking any medications for spasticity management. exclusion criteria: 1. recent change in the use of narcotic, anti-inflammatory or pain medication 2. unstable medical conditions or any other clinical observation that may affect the candidate's performance, health, safety or the ability to participate in the study, as determined by the treating therapist 3. history of sleep apnea 4. active participation in another movement research study or therapy program 5. anti-spasticity drug injection less than 3 months, prior to beginning treatment 6. musculoskeletal pain that interferes with participation in study 7. women who are currently, may be or planning on becoming pregnant
compass course: covid-19

Conditions: COVID-19

Summary: a group of clinicians and researchers developed an 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. the 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after session 7. the intervention, called the compass course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives. participating in this research will involve an introduction session, where informed consent will be obtained, followed by the 8-session intervention for 9 sessions in total. a team composed of researchers from courage kenny rehabilitation institute (ckri) propose to recruit a convenience sample of individuals who were hospitalized with covid-19 to evaluate the efficacy of administering the compass course to a novel population, to improve psychological well-being, engagement in everyday activities, and purpose in life. a focus group will be scheduled 2 months after the completion of the compass course. this session is composed of brief questionnaires and designed to obtain post-course data to help evaluate the compass course intervention.


Eligibility criteria:
inclusion criteria: * 18 - 80 years of age; * are part of the allina health covid research registry or are receiving/have received therapy services for covid-19 related sequelae at ckri; * english speaking * graduated from high school * able to see, hear, speak (with or without assistive devices) * access to computer or tablet and adequate internet connection to participate in video conference * has an email address; * own a smartphone with one of the following operating system versions: ios 9.0 - 9.3, 10.0 - 10.3, 12, 13.3, 13.7, 14.0 - 14.4 or later android 8.0 - 8.1.0, 9, 10, 11 or later * agree to use personal smartphone to download mema application and respond to application notifications (mema is described in sections 3.2.3.1 and 3.2.4.2.2); * willing and able to commit to attend all intervention sessions exclusion criteria: * history of neurologic disorder (such as stroke or brain injury) with residual impairments that likely interfere with learning; * any medical condition (physical or mental health) that interferes with the performance of everyday activities and roles.

Keywords: purpose in life